BLINCYTO® (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Portfolio Pulse from
Amgen announced that adding BLINCYTO® to chemotherapy significantly improves disease-free survival in pediatric patients with B-cell precursor acute lymphoblastic leukemia, with a 96% three-year survival rate.
December 07, 2024 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amgen's BLINCYTO® has shown significant improvement in disease-free survival rates for pediatric B-ALL patients, potentially boosting the company's reputation and stock value.
The positive results from the Phase 3 study of BLINCYTO® in pediatric leukemia patients are likely to enhance Amgen's reputation in oncology, potentially leading to increased demand and a positive impact on stock prices.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100